ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …

The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …

The emergence of Omicron sublineages impacts the therapeutic efficacy of anti-severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) …

Due to numerous mutations in the spike protein, the SARS-CoV-2 variant of concern
Omicron (B. 1.1. 529) raises serious concerns since it may significantly limit the antibody …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

ABSTRACT The SARS-CoV-2 Omicron variant is characterized by substantial changes in
the antigenic structure of the Spike (S) protein. Therefore, antibodies induced by primary …

As we have throughout the COVID-19 pandemic, the US Food and Drug Administration has
used the best available science as the virus has evolved to make informed decisions with …

The replacement of the Omicron BA. 1 variant of SARS-CoV-2 by the BA. 2 and the rapid
growth of the BA. 5 sub lineage, which have both different sets of mutations in the spike …

On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …